These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35785180)

  • 1. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
    Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
    Front Oncol; 2022; 12():901797. PubMed ID: 35785180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
    J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
    [No Abstract]   [Full Text] [Related]  

  • 3. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
    Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
    Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line Treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
    Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis.
    Qiao L; Liu Q; Huang C
    Medicine (Baltimore); 2023 Jul; 102(27):e33880. PubMed ID: 37417642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
    Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
    AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
    Deng L; Li Z; Zhang H; Huang H; Hu J; Liu L; Liu T; Jin J; Zhu Z; Li W; Huang Z; Huang W; Zhou K; Yang H; Zhang M; Ding K; Zhou H; Hu Y; Shuang Y; Cao J; Gao S; Li D; Sun Z; Zhang Q; Yi S; Ji C; Zhang L; Hou C; Du Y; Wang W; Zhao R; Song Y; Zhu J
    Am J Hematol; 2023 Nov; 98(11):1742-1750. PubMed ID: 37647123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
    Xu W; Zhou K; Wang T; Yang S; Liu L; Hu Y; Zhang W; Ding K; Zhou J; Gao S; Xu B; Zhu Z; Liu T; Zhang H; Hu J; Ji C; Wang S; Xia Z; Wang X; Li Y; Song Y; Ma S; Tang X; Zhang B; Li J
    Am J Hematol; 2023 Apr; 98(4):571-579. PubMed ID: 36683422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.
    Yu H; Wang X; Li J; Ye Y; Wang D; Fang W; Mi L; Ding N; Wang X; Song Y; Zhu J
    Mol Ther Oncolytics; 2021 Jun; 21():158-170. PubMed ID: 33981831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets and treatments in primary CNS lymphoma.
    von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
    Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
    Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
    Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
    Cao XX; Jin J; Fu CC; Yi SH; Zhao WL; Sun ZM; Yang W; Li DJ; Cui GH; Hu JD; Liu T; Song YP; Xu B; Zhu ZM; Xu W; Zhang MZ; Tian YM; Zhang B; Zhao RB; Zhou DB
    EClinicalMedicine; 2022 Oct; 52():101682. PubMed ID: 36313145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.
    Ma J; Lin Z; Ding T; Li Q; Zhang M; Kang H; Johnston PB; Ma Y; Chen B
    Front Oncol; 2022; 12():938421. PubMed ID: 35898888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
    Rubenstein JL; Geng H; Fraser EJ; Formaker P; Chen L; Sharma J; Killea P; Choi K; Ventura J; Kurhanewicz J; Lowell C; Hwang J; Treseler P; Sneed PK; Li J; Wang X; Chen N; Gangoiti J; Munster PN; Damato B
    Blood Adv; 2018 Jul; 2(13):1595-1607. PubMed ID: 29986852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.